Next-Generation Sequencing of Lung Cancer EGFR Exons 18-21 Allows Effective Molecular Diagnosis of Small Routine Samples (Cytology and Biopsy)-Reference-Cited by-同舟云学术

Next-Generation Sequencing of Lung Cancer EGFR Exons 18-21 Allows Effective Molecular Diagnosis of Small Routine Samples (Cytology and Biopsy)

Published:2013-12-23 Issue:12 Volume:8 Page:e83607
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

de Biase Dario,Visani Michela,Malapelle Umberto,Simonato Francesca,Cesari Valentina,Bellevicine Claudio,Pession Annalisa,Troncone Giancarlo,Fassina Ambrogio,Tallini Giovanni

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference68 articles.

1. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;TJ Lynch;N Engl J Med,2004

2. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;JG Paez;Science,2004

3. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS);M Fukuoka;J Clin Oncol,2011

4. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial;T Mitsudomi;Lancet Oncol,2010

5. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;TS Mok;N Engl J Med,2009

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular testing in lung cancer;Diagnostic Molecular Pathology;2024

2. Experience in Molecular Testing Using FNA Cytology in EU Countries;Thyroid FNA Cytology;2023

3. Enhanced ultrasound-guided versus non-enhanced ultrasound-guided percutaneous needle biopsy in tissue cellularity of lung malignancies: a propensity score matched study;Quantitative Imaging in Medicine and Surgery;2022-11

4. Expert opinion on NSCLC small specimen biomarker testing — Part 1: Tissue collection and management;Virchows Archiv;2022-07-20

5. Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer;Lung Cancer;2022-04